Testim is an testosterone-based drug owned by Auxilium Pharms Llc. The drug was first authorised for market use on October 31, 2002. Testim is available in gel transdermal dosage forms and can be used as a method for the administration of testosterone.
The generic versions of Testim are expected to be released after January 18, 2025. This is due to the expiry of the last patent, US7320968, pharmaceutical composition, on this date.
Testim is used to aid in the administration of testosterone. Its active ingredient, testosterone, contributes to its effectiveness by supplementing or replacing the testosterone that is naturally made in the body.
Testim holds a total of 10 drug patents of which 9 have already expired. The last patent, US7320968, titled 'Pharmaceutical composition', will expire on January 18, 2025, making the release of Testim generic possible. Below are the details of the patent: